Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

TAK-137 5 mg tablet, TAK-137 placebo tablet

Phase 1 · small molecule · Healthy Japanese Adult Male

TAK-137 5 mg tablet, TAK-137 placebo tablet for Healthy Japanese Adult Male is a Phase 1 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 1 small molecule terminated

Internal code TAK-137/CPH-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Japanese Adult Male
Status
terminated
Trials
1